Jean-Louis Dasseux
Presidente en Cerenis Therapeutics, Inc. .
Origen de la red de primer grado Jean-Louis Dasseux.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 19 | |
Cerenis Therapeutics, Inc.
Cerenis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Jean-Louis Dasseux a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
MORGAN STANLEY | Investment Managers | Corporate Officer/Principal | |
ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Operating Officer Corporate Officer/Principal | |
Quintiles, Inc. (California)
Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA. | Medical/Nursing Services | Corporate Officer/Principal | |
IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member | |
OXFORD BIOMEDICA PLC | Biotechnology | Director/Board Member | |
Dr. Reddy's Research & Development BV
Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Yale University | College/University | Graduate Degree Doctorate Degree | |
University of Michigan | College/University | Masters Business Admin Corporate Officer/Principal | |
ABLYNX | Biotechnology | Director/Board Member Director/Board Member | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member | |
Actelion Pharmaceuticals UK Ltd.
Actelion Pharmaceuticals UK Ltd. Medical DistributorsDistribution Services Actelion Pharmaceuticals UK Ltd. discovers, develops, and markets drugs. Its products are Tracleer for the treatment of pulmonary arterial hypertension and Zavesca, which is used to treat Type 1 Gaucher disease. The company is headquartered in London, UK. | Medical Distributors | Chief Operating Officer | |
Organon Pharma (UK) Ltd.
Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Pharmaceuticals: Major | Sales & Marketing | |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ESSEC Business School | College/University | Undergraduate Degree Undergraduate Degree | |
Politehnica University of Bucharest | College/University | Doctorate Degree | |
Institut de Contrôle de Gestion | College/University | Graduate Degree | |
Weill Cornell Medical College | College/University | Director/Board Member Corporate Officer/Principal | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
STJ Advisors LLP
STJ Advisors LLP Investment ManagersFinance STJ Advisors LLP provides capital markets advisory services. The private company is based in London, UK and has subsidiaries in Hong Kong. The British company was founded in 2008 by John James Moore St. John. | Investment Managers | Corporate Officer/Principal | |
BIOTALYS NV | Chemicals: Agricultural | Director/Board Member Director/Board Member | |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
CMR Surgical Ltd.
CMR Surgical Ltd. Medical SpecialtiesHealth Technology CMR Surgical Ltd. develops universal robotic system for minimal access surgery. The firm is presently evaluating the ability of the versius system to perform upper GI, gynaecological, colorectal and renal surgery in cadaveric trials. The company was founded by Martin Frost and Mark Slack in January 2014 and is headquartered in Cambridge, the United Kingdom. | Medical Specialties | Director/Board Member | |
BioSavita, Inc.
BioSavita, Inc. BiotechnologyHealth Technology BioSavita, Inc. operates as a biotechnology company, which develops a technology solution for the development of therapeutic antibodies. It focuses on developing a technology platform based on yeast (saccharomyces cerevisiae) expression systems that accelerate the discovery and development of antibody therapeutics and recombinant proteins. The company was founded by Nalini Ghag-Motwani in 1993 and is headquartered in Plymouth, MI. | Biotechnology | Chief Operating Officer | |
IXALTIS SAS
IXALTIS SAS Pharmaceuticals: MajorHealth Technology IXALTIS SAS develops therapeutics to treat genitourinary tract disorders with unsatisfied medical need. The company was founded by Christian Chavy, Philippe Lluel, Roberto Gradnik, Stefano Palea, Pascal Rischmann, and Xavier Gamé in 2012 and is headquartered in Archamps, France. | Pharmaceuticals: Major | Founder | |
Creabilis SA | Director/Board Member | ||
GENKYOTEX SA. | Pharmaceuticals: Major | Director/Board Member | |
Access Vascular, Inc.
Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Medical Specialties | Director/Board Member | |
DNA Script SAS
DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member | |
OCUPHIRE PHARMA, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Noema Pharma AG
Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
ImmunoRx Pharma, Inc.
ImmunoRx Pharma, Inc. Pharmaceuticals: MajorHealth Technology ImmunoRx Pharma, Inc. manufactures pharmaceutical products. The company is based in Wilmington, DE. The CEO of the company is Juan Felipe Velasquez. | Pharmaceuticals: Major | Director/Board Member | |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Pharmaceuticals: Major | Director/Board Member | |
MOONLAKE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
Creative Pharma Advisors LLC | Founder |
Estadísticas
Internacional
Estados Unidos | 19 |
Reino Unido | 10 |
Francia | 8 |
Suiza | 7 |
Bélgica | 3 |
Sectorial
Health Technology | 37 |
Consumer Services | 7 |
Finance | 4 |
Health Services | 2 |
Distribution Services | 2 |
Operativa
Director/Board Member | 156 |
Corporate Officer/Principal | 56 |
Independent Dir/Board Member | 33 |
Chairman | 25 |
Chief Executive Officer | 21 |
Las relaciones más conectadas
Insiders | |
---|---|
Johan Rutger Christenson | 35 |
Catherine Moukheibir | 29 |
Jean-Pierre Garnier | 28 |
Michael Davidson | 27 |
Mary L. Campbell | 27 |
Denis Lucquin | 26 |
Marc Rivière | 18 |
Christian Chavy | 18 |
Richard Pasternak | 16 |
Alexandra Goll | 14 |
Barbara Yanni | 13 |
Emmanuel Huynh | 8 |
Daniela Oniciu | 8 |
Narendra D. Lalwani | 8 |
Laura Coruzzi | 7 |
- Bolsa de valores
- Insiders
- Jean-Louis Dasseux
- Conexiones Empresas